Abstracts tagged "longitudinal studies"

Abstract Number: 712 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort
Mary Gibson¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Colton Pence¹, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: TNF-α inhibitor therapy is recommended by ASAS/EULAR guidelines for ankylosing spondylitis (AS) patients with moderate-to-high disease activity despite inadequate response to NSAIDs in addition…
Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Michael Morgan¹, Andreas Reimold², Ted R. Mikuls³, Gail Kerr⁴ and Grant W. Cannon⁵, ¹Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Washington DC VA and Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…
Abstract Number: 2398 • 2014 ACR/ARHP Annual Meeting
Continued Participation in a 10-Year Tight Control Treat-to-Target Study in Rheumatoid Arthritis: Why Keep Patients Doing Their BeSt?
I.M. Markusse¹, L. Dirven², T.H.E. Molenaar³, N. Riyazi⁴, P.B.J. de Sonnaville⁵, P.J.S.M. Kerstens⁶, W.F. Lems⁷, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: To identify risk factors for premature study termination and patients’ motives for adherence to a long term follow-up clinical trial in rheumatoid arthritis (RA).…
Abstract Number: 2248 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes, Neuropathic Pain and Patient Satisfaction over a 15 Year Period Following Primary Tka: A Repeat-Cross-Sectional Analysis
Anne Lübbeke¹, Matthieu Zingg², Daniel Fritschy¹, Pierre Hoffmeyer¹ and Hermes Miozzari², ¹Orthopaedic Surgery, Geneva University Hospitals, Geneva, Switzerland, ²Orthopaedics, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose Studies evaluating patient-reported long term outcomes (>10 years) after primary TKA are lacking. Moreover, variability in patient satisfaction after TKA has been reported for…
Abstract Number: 2053 • 2014 ACR/ARHP Annual Meeting
Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study
Joëlle van den Hoek^1,2, Hendriek C. Boshuizen³, Leo D. Roorda⁴, Gerard J. Tijhuis⁵, Mike T. Nurmohamed⁵, Trudi van den Bos² and Joost Dekker^6,7, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁷Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher mortality risk than the general population, with similar patterns over the last decades. However, more recent…
Abstract Number: 2054 • 2014 ACR/ARHP Annual Meeting
Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Follow-up Period: The Role of Specific Comorbidities
Joëlle van den Hoek¹, Leo D. Roorda², Hendriek C. Boshuizen³, Gerard J. Tijhuis⁴, Trudi van den Bos⁵ and Joost Dekker⁶, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Comorbidity in patients with Rheumatoid Arthritis (RA) is highly prevalent and plays an important role in determining RA related outcomes. Several studies have reported…
Abstract Number: 2047 • 2014 ACR/ARHP Annual Meeting
No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort
Shivani Sahni¹, Kelsey Mangano², Katherine Tucker³, Caroline Fox⁴, Douglas P. Kiel⁵, Xiaochun Zhang⁶ and Marian T. Hannan¹, ¹Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Clinical Laboratory & Nutritional Sciences, Center for Population Health & Health Disparities, University of Massachusetts, Lowell, MA, ⁴Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA
Background/Purpose: Serum uric acid (UA) has been linked with fractures in older men. Three different studies in older men showed conflicting results. The objective…
Abstract Number: 1286 • 2014 ACR/ARHP Annual Meeting
The Natural Course of Physical Function in People with Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Britt Elin Øiestad¹, Daniel White², Ross Booton³, Jingbo Niu³, Yuqing Zhang⁴, James C. Torner⁵, Cora E. Lewis⁶, Michael C. Nevitt⁷, Michael P. Lavalley⁸ and David T. Felson⁹, ¹Department of Orthopedics, Oslo University Hospital, 0407 Oslo, Norway, ²Clinical Epidemiology Training, Boston Univ School of Med, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Epidemiology, University of Iowa, Iowa City, Iowa City, IA, ⁶Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁷Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁸Biostatistics, Boston University, Boston, MA, ⁹Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Longitudinal studies of people with knee osteoarthritis (OA) have reported stable or improved physical function, contrary to the progressive degenerative nature of OA. The…
Abstract Number: 1062 • 2014 ACR/ARHP Annual Meeting
Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort
Christopher Sparks¹, Robert Moots¹, Eftychia Psarelli², Tom Huizinga³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Cancer Research UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Increased adiposity is associated with increased production of pro-inflammatory adipokines and raised inflammatory markers. As a result, standard disease activity scores (DAS) may be…
Abstract Number: 907 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis
Hilde B. Hammer¹ and Tore K. Kvien², ¹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background/Purpose: Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 2654 • 2014 ACR/ARHP Annual Meeting
Cognitive Function in Systemic Lupus Erythematosus Patients with Past History of Neuropsychiatric Manifestations : A Longitudinal Study
Yang Gao¹, Yi Lo¹, Jacky Wan², Esther YY Lau² and Mo Yin Mok¹, ¹Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ²Department of Psychology, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Cognitive impairment is commonly reported in patients with systemic lupus erythematosus (SLE) and its associations with neuropsychiatric involvement (NPSLE) and psychiatric factors have been…
Abstract Number: 2763 • 2013 ACR/ARHP Annual Meeting
Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis
Inmaculada del Rincon¹, Roy W. Haas², Jose Felix Restrepo³, Daniel F. Battafarano⁴, Daniel H. O'Leary⁵, Emily Molina¹ and Agustin Escalante⁶, ¹Rheumatology, University of Texas Health Science Center, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁴Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ⁵Radiology, Tufts University-Boston Campus, Boston, MA, ⁶Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher mortality than do persons of the same age and sex without RA. This is due in part…
Abstract Number: 2752 • 2013 ACR/ARHP Annual Meeting
Good, Moderate and Poor Outcome Trajectories Of Pain Severity In Early Symptomatic Knee Osteoarthritis; 5 Year Follow-Up Of Check study
Janet Wesseling¹, Alex N. Bastick², Sita M.A. Bierma-Zeinstra³ and Johannes W.J. Bijlsma⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ³Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Knee pain is often the first sign of knee OA (osteoarthritis) and it is known that its course can be very different between patients over…
Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Ketti K. Terry⁴, Hiroyuki Nakamura⁵, Yukako Ohno⁵, David Gruben⁴, Birgitta Benda⁶, Lisy Wang⁴ and Richard Riese⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].